Literature DB >> 33200448

Adenosine A2A Receptor Occupancy by Long-Term Istradefylline Administration in Parkinson's Disease.

Kenji Ishibashi1,2, Yoshiharu Miura2, Kei Wagatsuma1, Jun Toyohara1, Kiichi Ishiwata1,3,4, Kenji Ishii1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33200448      PMCID： PMC7894182          DOI： 10.1002/mds.28378

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  3 in total

1.  Occupancy of adenosine A2A receptors by istradefylline in patients with Parkinson's disease using 11C-preladenant PET.

Authors:  Kenji Ishibashi; Yoshiharu Miura; Kei Wagatsuma; Jun Toyohara; Kiichi Ishiwata; Kenji Ishii
Journal:  Neuropharmacology       Date:  2018-09-22       Impact factor: 5.250

Review 2.  The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease.

Authors:  Jiang-Fan Chen; Rodrigo A Cunha
Journal:  Purinergic Signal       Date:  2020-03-31       Impact factor: 3.765

3.  Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.

Authors:  Yoshikuni Mizuno; Tomoyoshi Kondo
Journal:  Mov Disord       Date:  2013-03-11       Impact factor: 10.338
  3 in total
  2 in total

1.  Discovery of Pyridone-Substituted Triazolopyrimidine Dual A2A/A1 AR Antagonists for the Treatment of Ischemic Stroke.

Authors:  Mei-Lin Tang; Zi-Hao Wen; Jing-Huan Wang; Mei-Ling Wang; Heyanhao Zhang; Xin-Hua Liu; Lin Jin; Jun Chang
Journal:  ACS Med Chem Lett       Date:  2022-02-21       Impact factor: 4.345

2.  Adenosine A2A Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease.

Authors:  Kenji Ishibashi; Yoshiharu Miura; Kei Wagatsuma; Jun Toyohara; Kiichi Ishiwata; Kenji Ishii
Journal:  Mov Disord       Date:  2022-01-09       Impact factor: 9.698
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.